Facilitating Self-Control of Substance Abuse Related Brain Activity Through Real-Time Monitoring of fMRI Signals (R21/R33)

The summary for the Facilitating Self-Control of Substance Abuse Related Brain Activity Through Real-Time Monitoring of fMRI Signals (R21/R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Facilitating Self-Control of Substance Abuse Related Brain Activity Through Real-Time Monitoring of fMRI Signals (R21/R33): Purpose. The National Institute on Drug Abuse (NIDA), through the issuance of this Request for Applications (RFA), seeks to encourage exploratory (i.e., descriptive, hypothesis-generating, and developmental) research focusing on the use of real time functional magnetic resonance imaging (rt-fMRI) in humans so that subjects can learn to modulate their own brain activity and monitor and control (modulate) activity of brain regions relevant to substance abuse. Proposals may incorporate development, implementation, and dissemination of requisite technology and methods as well as feasibility testing in healthy human subjects or substance abusers. Because applications are to be exploratory in nature, pilot data that provide support for the proposed hypotheses and aims (i.e., Proof of Concept) are not required nor is it expected that data to support the hypotheses be provided. However, applicants are encouraged to provide evidence that they have the capability to conduct fMRI studies (i.e., Proof of Feasibility) by documenting the availability of needed resources, the training and experience of the investigative team, and/or the conduct of related studies. Such studies would be optimally conducted by interdisciplinary teams that include researchers with brain imaging, cognitive neuroscience, behavioral analysis, and treatment expertise, Investigators from different institutions may submit linked applications to support collaborative projects. Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH R21/R33 Phased Innovation Award ((R21 [Phase I]/R33 [Phase II]) grant mechanism. The Phased Innovation (R21/R33) mechanism provides support for a first phase (R21) for technical development and a second phase (R33) for technology application and demonstration of utility in a larger subject sample. The outcome of the first phase (R21) should be data demonstrating the feasibility of the technology or approach proposed for the second phase, and the second phase (R33) should have the goal of generating proof-of-concept data. Funds Available and Anticipated Number of Awards. This FOA has $3M set aside to fund meritorious applications that address the goals of this solicitation. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. It is anticipated that between 6 10 proposals might be funded under this solicitation. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend on the number, quality, duration, and costs of the applications received. Budget and Project Period. Direct costs for these Phased Innovation Awards are limited to $200,000 per year for the R21 phase and $400,000 per year for the R33 phase. These budget limits also apply to each individual submission within a set of linked applications. The amount of funds requested and the distribution of funds across linked applications should be tailored to the needs of the project. The R21 phase can be up to two years, and the R33 phase can be up to 3 years. For the R21/R33 Phased Innovation Award application, the initial review group will evaluate the specific goals for each phase and the feasibility milestones that would justify expansion to the R33 phase. A single priority score will be assigned to each scored application. Eligible Institutions/Organizations. Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organization; Eligible agencies of the Federal government; Faith-based or community based organizations.) Eligible Project Directors/Principal Investigators (PDs/PIs): Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Number of PDs/PIs. More than one PD/PI, or multiple PDs/PIs, may be designated on the application. Renewals and Resubmissions: No Renewal or Revision applications will be accepted. Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct.